BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the BioCentury NewsMakers in the Biotech Industry Conference in New York City on Thursday, September 6, 2007 at 10:30 a.m. ET.

Interested parties may access a live audio webcast of the presentation via the investor section of the BioMarin website, http://www.bmrn.com/. A replay of the presentation will be archived on the site for at least one week following the presentation.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio is comprised of two approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation. Investigational product candidates include Kuvan(TM) (sapropterin dihydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU), and 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease.

  Naglazyme(R) is a registered trademark of BioMarin Pharmaceutical Inc.

  Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

   Contacts:

   Investors                                 Media
   Eugenia Shen                              Susan Berg
   BioMarin Pharmaceutical Inc.              BioMarin Pharmaceutical Inc.
   (415) 506-6570                            (415) 506-6594

First Call Analyst:
FCMN Contact: eshen@bmrn.com

SOURCE: BioMarin Pharmaceutical Inc.